We are live on ! Find out more
OIM

Oracle Investment Management Portfolio holdings

AUM $168M
1-Year Est. Return 42.86%
This Fund
S&P 500
This Quarter Est. Return
+96.39%
1 Year Est. Return
+42.86%
3 Year Est. Return
+864.89%
5 Year Est. Return
+1,153.35%
10 Year Est. Return
+22,228.86%
AUM
$457M
AUM Growth
+$43.1M
Cap. Flow
-$35M
Cap. Flow %
-7.67%
Top 10 Hldgs %
96.28%
Holding
23
New
2
Increased
4
Reduced
7
Closed
4

Top Buys

Rank Stock Value
1
AMRN
Amarin Corp
AMRN
+$2.22M
2
VRAY
ViewRay, Inc.
VRAY
+$2.13M
3
CFRX
ContraFect Corporation
CFRX
+$2.12M

Top Sells

Rank Stock Value
1
QDEL icon
QuidelOrtho
QDEL
+$32.2M
2
TSRO
TESARO, Inc.
TSRO
+$8.7M
3
ADAP
Adaptimmune Therapeutics
ADAP
+$5.2M
4
AXDX
Accelerate Diagnostics
AXDX
+$1.92M
5
ARNA
Arena Pharmaceuticals Inc
ARNA
+$1.74M

Sector Composition

Rank Sector Weight
1 Healthcare 98.88%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
QDEL icon
1
QuidelOrtho
QDEL
$1.14B
$124M 27.16%
1,903,558
-461,325
-20% -$32.2M
AXDX
2
DELISTED
Accelerate Diagnostics
AXDX
$96.1M 21.04%
418,715
-8,693
-2% -$1.92M
AMRN
3
Amarin Corp
AMRN
$293M
$95.2M 20.84%
292,508
+29,441
+11% +$2.22M
PACB icon
4
Pacific Biosciences
PACB
$432M
$50.8M 11.12%
9,387,634
-317,127
-3% -$1.36M
TSRO
5
DELISTED
TESARO, Inc.
TSRO
$20.2M 4.42%
517,235
-246,300
-32% -$8.7M
BIOL
6
DELISTED
Biolase, Inc.
BIOL
$12.8M 2.8%
2,469
– –
OPK icon
7
Opko Health
OPK
$1.25B
$12.8M 2.79%
3,686,194
– –
ADAP
8
DELISTED
Adaptimmune Therapeutics
ADAP
$12.2M 2.66%
897,494
-496,249
-36% -$5.2M
CFRX
9
DELISTED
ContraFect Corporation
CFRX
$8.8M 1.93%
5,313
+1,282
+32% +$2.12M
VRML
10
DELISTED
Vermillion, Inc.
VRML
$6.98M 1.53%
9,825,289
– –
SLNO
11
DELISTED
Soleno Therapeutics
SLNO
$5.27M 1.15%
162,537
– –
AGEN
12
Agenus
AGEN
$275M
$3.21M 0.7%
76,402
– –
AXDX
13
CALL
DELISTED
Accelerate Diagnostics
AXDX
$2.99M 0.66%
96,790
+36,030
+59% +$7.97M
BIIB icon
14
Biogen
BIIB
$30.4B
$2.25M 0.49%
6,368
– –
VRAY
15
DELISTED
ViewRay, Inc.
VRAY
$2.03M 0.44%
+216,862
New +$2.13M
KDNY
16
DELISTED
Chinook Therapeutics, Inc. Common Stock
KDNY
$820K 0.18%
22,308
-37,101
-62% -$1.19M
EPZM
17
DELISTED
Epizyme, Inc
EPZM
$306K 0.07%
28,884
-98,259
-77% -$1.12M
QDEL icon
18
CALL
QuidelOrtho
QDEL
$1.14B
$58K 0.01%
175,000
+69,300
+66% +$4.84M
PACB icon
19
CALL
Pacific Biosciences
PACB
$432M
$46K 0.01%
+50,000
New +$215K
ARNA
20
CALL
DELISTED
Arena Pharmaceuticals Inc
ARNA
– –
-100,000
Closed -$295K
ARNA
21
DELISTED
Arena Pharmaceuticals Inc
ARNA
– –
-39,887
Closed -$1.74M
TSRO
22
CALL
DELISTED
TESARO, Inc.
TSRO
– –
-11,000
Closed -$66K
MZOR
23
CALL
DELISTED
Mazor Robotics Ltd.
MZOR
– –
-135,300
Closed -$697K

Similar funds

BIO
Blue Investment Opportunities Miami Beach, Florida $168M AUM 21.32% 1-Year Est. Return
OBWA
Oak Barrel Wealth Advisory Reston, Virginia $167M AUM
EECFX
EnCap Energy Capital Fund XII Houston, Texas $169M AUM
PW
Pandora Wealth Oakbrook Terrace, Illinois $165M AUM 18.5% 1-Year Est. Return
PWA
Principia Wealth Advisory Dallas, Texas $160M AUM 37.01% 1-Year Est. Return
AIMU
Allianz Investment Management US Minneapolis, Minnesota $160M AUM 4.75% 1-Year Est. Return
HIA
Harvest Investment Advisors Tallahassee, Florida $176M AUM
ACA
AG Campbell Advisory Baltimore, Maryland $158M AUM

Oracle Investment Management's Q3 2018 Portfolio in Review

As of Q3 2018, Oracle Investment Management held 23 positions worth $457M, up 10% from $414M the previous quarter. Its ten largest holdings account for 96% of the portfolio.

Oracle Investment Management withdrew a net $35M in Q3 2018, closing 4 positions and reducing 7 holdings. Its most notable exit was Arena Pharmaceuticals Inc, an estimated $1.74M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 99% of assets, down from 99% a quarter earlier.

Against the trend, Oracle Investment Management opened a new position in ViewRay, Inc. worth $2.03M.

  • Oracle Investment Management's largest Q3 2018 buy was ViewRay, Inc.: 216,862 shares worth $2.03M.
  • Oracle Investment Management added most to Amarin Corp in Q3 2018, an estimated $2.22M increase.
  • Oracle Investment Management's biggest Q3 2018 reduction was QuidelOrtho, cutting an estimated $32.2M.
  • Oracle Investment Management fully exited Arena Pharmaceuticals Inc in Q3 2018, selling an estimated $1.74M.
  • Oracle Investment Management's ten largest holdings make up 96% of its $457M portfolio in Q3 2018.
  • Oracle Investment Management opened 2 new positions and closed 4 in Q3 2018.
  • Oracle Investment Management's portfolio value rose 10% quarter-over-quarter to $457M.

Based on Oracle Investment Management's 13F filing for Q3 2018, filed 14 Nov 2018.